Optimizing the Development of Antipsychotic Drugs
Published on 28. July 1997
Book
Hardback
216 pages
978-0-471-97011-8 (ISBN)
Description
This work provides information on developing novel anxiolytics. Recommendations for developing anxiolytic compounds are included based on the experience of the authors. Numerous compounds are in the precli nical pipeline and the pharmaceutical industry, as well as anyone interested in the design and conduct of schizophrenia clinical trials, are waiting for these research results.
More details
Language
English
Place of publication
Chichester
United Kingdom
Publishing group
John Wiley and Sons Ltd
Target group
Professional and scholarly
Illustrations
Illustrations
Dimensions
Height: 235 mm
Width: 156 mm
Weight
440 gr
ISBN-13
978-0-471-97011-8 (9780471970118)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Content
Section one: Worldwide market for antipsychotics. Section two: Developing atypical antipsychotics. Section three: Phase 1 clinical development and finding the dose. Section four: Clinical development and diagnosis. Section five: Neuropsychological testing in schizophrenia. Section six: An overview of accelerated antipsychotic drug development.